& Trump, D
In addition to weight reduction, retatrutide has been associated with improvements in glycemic control and other cardiometabolic parameters in adults with obesity
Semaglutide example (maintenance dose): Brand-name Wegovy: ~$1,350/month = ~$16,200/year Compounded (503B): ~$300/month average = ~$3,600/year Annual savings: approximately $12,600 Percentage savings: approximately 78% Tirzepatide example (maintenance dose): Brand-name Zepbound: ~$1,060/month = ~$12,720/year Compounded (503B): ~$375/month average = ~$4,500/year Annual savings: approximately $8,220 Percentage savings: approximately 65% Over a multi-year treatment course - and GLP-1 treatment is typically long-term - these savings compound dramatically
BBB rating: F
synthesize Gamma-aminobutyric acid (GABA), a crucial inhibitory neurotransmitter (Zheng et al., 2023)
This improves performance, reduces muscle glycogen consumption, and decreases lactic acid accumulation